Submit Manuscript  

Article Details

Fibroblast Growth Factor: Promising Target for Schizophrenia

[ Vol. 21 , Issue. 13 ]


Ali Talaei, Tahereh Farkhondeh and Fatemeh Forouzanfar*   Pages 1344 - 1353 ( 10 )


Schizophrenia is one of the most debilitating mental disorders around the world. It is characterized by neuroanatomical or biochemical changes. The role of the fibroblast growth factors (FGFs) system in schizophrenia has received considerable attention in recent years. Various changes in the gene expression and/or level of FGFs have been implicated in the etiology, symptoms and progression of schizophrenia. For example, studies have substantiated an interaction between FGFs and the signaling pathway of dopamine receptors. To understand the role of this system in schizophrenia, the databases of Open Access Journals, Web of Science, PubMed (NLM), LISTA (EBSCO), and Google Scholar with keywords including fibroblast growth factors, dopamine, schizophrenia, psychosis, along with neurotrophic were searched. In conclusion, the FGF family represent molecular candidates as new drug targets and treatment targets for schizophrenia.


Fibroblast growth factors, dopamine, schizophrenia, psychosis, neurotrophic, antipsychotic drugs.


Psychiatry and Behavioral Sciences Research Center, Mashhad University of Medical Sciences, Mashhad, Cardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Neuroscience Research Center, Mashhad University of Medical Sciences, Mashhad

Graphical Abstract:

Read Full-Text article